Showing results (491-500 of 579) with videos related to

Sort By:
Pageof 58
Blood|July 25, 2022
The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysisArmin Ghobadi, Michael Slade, Hagop Kantarjian, et al.
Blood Neoplasia|September 22, 2025
Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1Courtney D DiNardo, Wei-Ying Jen, Guillermo Montalban-Bravo, et al.
Leukemia & Lymphoma|September 21, 2020
Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosisMusa Yilmaz, Hagop M Kantarjian, Gokce Toruner, et al.
Blood Cancer Journal|May 2, 2022
Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AMLMusa Yilmaz, Hagop Kantarjian, Nicholas J Short, et al.
The Lancet. Haematology|April 28, 2022
Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort studyCurtis A Lachowiez, Patrick K Reville, Hagop Kantarjian, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 30, 2025
Outcomes of Patients With IDH1-Mutated Myeloid Neoplasms Treated With OlutasidenibKelly S Chien, Sanam Loghavi, Koji Sasaki, et al.
Leukemia & Lymphoma|July 19, 2017
A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemiaNicholas J Short, Hagop Kantarjian, Farhad Ravandi, et al.
American Journal of Hematology|February 24, 2024
Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trialIssa F Khouri, Kamal Alzahrani, Hagop Kantarjian, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 15, 2021
Myeloid/lymphoid neoplasms with FLT3 rearrangementGuilin Tang, Wayne Tam, Nicholas J Short, et al.
Blood|August 5, 2017
Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPNElias Jabbour, Nicholas J Short, Guillermo Montalban-Bravo, et al.
Pageof 58